GPAT4

Across TCGA pan-cancer cohorts, GPAT4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPAT4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GPAT4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPAT4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where GPAT4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.105	0.928	.003	32	view →
PDAC	DFS	Quartile	All	0.304	0.492	.010	13	view →
LUAD	DFS	Median	III,IV	0.728	0.343	.011	8	view →
HNSC	OS	Tertile	II,III,IV	0.945	0.753	.018	4	view →
UCEC	OS	Tertile	All	0.949	0.759	.030	2	view →
LSCC	OS	Tertile	All	1.000	0.931	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPAT4–CCRCC (DFS)

Open the CCRCC breakdown →